Currently out of the existing stock ratings of Peter Welford, 29 are a BUY (53.7%), 18 are a HOLD (33.33%), 7 are a SELL (12.96%).

Peter Welford

Work Performance Price Targets & Ratings Chart

Analyst Peter Welford, currently employed at JEFFERIES, carries an average stock price target met ratio of 51.11% that have a potential upside of 27.7% achieved within 376 days.

Peter Welford’s has documented 91 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 12-Nov-2024.

Wall Street Analyst Peter Welford

Analyst best performing recommendations are on CGEN (COMPUGEN).
The best stock recommendation documented was for PLX (PROTALIX BIOTHERAPEUTICS) at 9/6/2016. The price target of $8 was fulfilled within 156 days with a profit of $1.8 (29.03%) receiving and performance score of 1.86.

Average potential price target upside

of $33.89 (33.44%) on NVO (NOVO NORDISK A/S).
of $20.19 (23.81%) on NVS (NOVARTIS AG ADR).
of $8.76 (15.68%) on AZN (ASTRAZENECA PLC ADR).

AZN AstraZeneca PLC ADR GSK GlaxoSmithKline PLC ADR PLX Protalix Biotherapeutics CGEN Compugen GLPG Galapagos NV ADR GMAB Genmab AS NVO Novo Nordisk A/S NVS Novartis AG ADR SNY Sanofi ADR RHHBY Roche Holding Ltd ADR

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Andrew Berens (LEERINK)